Welcome to United Therapeutics Global Medical Affairs.

This website is a resource intended for U.S. healthcare professionals only. This site is intended to provide balanced, scientific, and evidence-based information to foster scientific exchange. United Therapeutics does not provide medical advice. It is the healthcare professional’s responsibility to use independent clinical judgment when making clinical decisions for individual patients.

This website may include information that has not been approved by the U.S. Food and Drug Administration. United Therapeutics does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling. For full prescribing information, including indications, contraindications, warnings, precautions, and adverse events, please refer to the FDA-approved product labeling.

Are you a U.S. Healthcare Professional?

 Skip to main content

FREEDOM EV Hemodynamics Sub-Study

690 participants with PAH who were taking a single oral PAH therapy

Sub-study

61 Participants volunteered for hemodynamics sub-study:

Oral treprostinil 34
Placebo 27

PA compliance

Bar graph of change in pulmonary arterial compliance from baseline with oral treprostinil vs. placebo. PA compliance increased by 26.4% with oral treprostinil and decreased by 6% with placebo. This difference is statistically significant with a p-value of 0.007.

p = 0.007

PVR

Bar graph of change in pulmonary vascular resistance from baseline with oral treprostinil vs. placebo. PVR decreased by 21.5% with oral treprostinil and decreased by 1.8% with placebo. This difference is statistically significant with a p-value of 0.02.

p = 0.02

CO

Bar graph of change in cardiac output from baseline with oral treprostinil vs. placebo. CO increased by 11.3% with oral treprostinil and decreased by 6.4% with placebo. This difference is statistically significant with a p-value of 0.005.

p = 0.005

Oral treprostinil
Placebo

Graphs represent change in geometric mean (%) from Baseline to Week 24